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Policy Brief 1:2011 
	  
Drawing on a 2-day interactive expert workshop held on 7-8 November 2011 at the ESRC 
Genomics Forum in Edinburgh under the Forum’s Bright Ideas Programme, and also 
drawing on interdisciplinary engagements between interested stakeholders in the Argentine 
and UK regenerative medicine field that have been ongoing for some four years, this Policy 
Brief explores key issues in the regulation of cellular products, and, drawing on the EU and 
UK experience, makes a number of recommendations for regulation in Argentina. 
	  
1
THE POLICY WORKSHOP & WORKING GROUP 
 
Scholars, regulators and other key actors in the Argentine and UK 
regenerative medicine field have been mutually engaged for some four 
years now.  Most recently, Fabiana Arzuaga (Arzuaga) was hosted by the 
ESRC Genomics Forum under its Bright Ideas Programme.1  On 7-8 
November 2011, Arzuaga and Shawn Harmon (Harmon), with support 
from the Genomics Forum, organised a 2-day interactive workshop with 
experts and scholars interested in the field (Working Group).2  The aims of 
the workshop were to: 
 
• explore the evolving regulatory state of affairs for regenerative 
medicine and cellular therapies in Argentina; 
 
• report on the findings of the Governing Emerging Technologies: 
Social Values and Stem Cell Regulation in Argentina project;3 
♠  Lecturer in Regulation & Risk, School of Law, University of Edinburgh; Research 
Fellow, AHRC/SCRIPT and ESRC/InnoGen, University of Edinburgh; Member of the Nova 
Scotia Bar; BA, Saint Mary’s University, Canada (1993); LLB, University of New 
Brunswick, Canada (1996); LLM, University of Edinburgh, UK (2004). 
♦  Chair of the Argentine Advisory Commission on Regenerative Medicine & Cellular 
Therapies, MINCYT; Doctoral Candidate, University of Buenos Aires. 
♣  Professor of Medical Jurisprudence, University of Edinburgh; Founding Director of 
the J. Kenyon Mason Institute for Medicine, Life Sciences and the Law; LLB, University of 
Glasgow, UK (1989); PhD, Glasgow University, UK (1997); Fellow of the Royal Society of 
Edinburgh. 
1  See http://www.genomicsnetwork.ac.uk/forum/. 
2  In addition to Arzuaga and Harmon, the Working Group consisted of Prof. Graeme 
Laurie, Prof. Joyce Tait (Innogen), Iain Gillespie (former OECD), John Purves (former 
EMA), Dr. Steve Sturdy (Genomics Forum), Dr. James Mittra (Innogen), and Ms. Carol 
George (SCRIPT). 
3  See http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/. 
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• draw on the experience of the UK and Europe with a view to 
formulating recommendations for proceeding in Argentina; and 
 
• offer participants an opportunity to reflect on the robustness of UK and 
EU regulatory mechanisms. 
 
After presentations from Arzuaga (on the Argentine social and regulatory 
context), Harmon (on the Argentine empirical data concerning values and 
regulatory ambitions), and John Purves (Purves)(on the EU medicinal products 
framework), the Working Group structured an open discussion around three 
live questions: 
 
1. What is the impact of law on innovation, and how might law be 
fashioned so it avoids inhibiting innovation? 
 
2. Is the UK/EU model for dealing with Advanced Therapy Medical 
Products (ATMPs) for hospital exemptions, whereby stem cell 
therapies can be administered to individual patients within a hospital 
using GMP practices, suitable for Argentina? 
 
3. Are cellular based materials best characterised as drugs, devices, 
transplant tissue, or a sui generis substance? 
 
After some wide-ranging discussions which took into consideration the 
international nature of science, the empirical evidence generated by the GET: 
Social Values Project (undertaken by Harmon and Arzuaga), and the specific 
experience of the participants, the following findings were reached generally 
agreed. 
 
DISCUSSION & FINDINGS 
 
Definitions & Boundaries 
Cellular products will (eventually), if the science progresses as desired, fall 
under different regulatory categories: they may be tissue that is transplanted, 
they may be medicinal products subjected to an manufacturing procedure, and 
they may also be combined with mechanical devices that are operated within 
and outwith the body.  They have (and will have) a unique nature.4  Thus, one 
issue in cellular products that requires careful consideration is definitions and 
product classifications and the boundaries between transplants and medicinal 
products.  The matter of classification is not yet settled. 
 
4  We are probably 15+ years away from cellular therapies that are anything more 
than patient-specific treatments, and we are farther off from therapies that are suitable for 
pharmacy-type trials and distribution. 
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The EU, through the European Medicines Agency (EMA), has classified 
cellular products as Advanced Therapy Medicinal Products (ATMPs).  Its 
approach, which draws on an array of Regulations, Technical Directives, and 
Guidelines, relies on early contact between regulators and industry to address 
matters of product classification, scientific uncertainty, and product 
certification for quality and non-clinical aspects.  Unfortunately, the European 
approach is rather fragmented (as evidenced by difficulties associated with 
clinical trials of cellular products). 
 
With respect to classifying some cellular products as ATMPs and thereby 
giving them operative space under the ‘hospital exemption’, Europe has 
experienced significant individual- or practitioner-based innovation in the 
devices field, which the hospital exemption was intended to permit, but there is 
no evidence of these innovations leading to practices that have been more 
broadly taken up, a fact which may not be surprising given the stage of 
scientific understanding, the availability of resources for product development, 
and the difficulty of transitioning to clinical  trials. 
 
Discourse & Engagement 
There is a tension between the desire for regulatory certainty and the need for 
regulatory flexibility.  In the cellular therapies setting, there is significant 
scientific/technical uncertainty, and so there will inevitably be regulatory 
uncertainty.  This makes communication between and amongst stakeholders 
essential.  The idea of open communications and debate is essential.   
Transparency is important for all stakeholders, to know who the other the 
stakeholders are and to consistently engage with them. 
 
The EU strength has been its recognition that the field will benefit from 
detailed consultation with ALL interested parties and that the evolution of 
scientific understanding will rely in no small part on the market (ie: the 
regulatory framework must not only address supply issues, but also demand 
issues and pressures as well).  The EU orphan drug regime is a good example 
of collectively tackling a problem rather than developing labyrinthine 
structures, and it is an approach that has been adopted for ATMPs.  The EU 
medicinal products regulatory system has evolved and a key to that evolution 
has been the involvement of patient/interest groups (ie: non-industry actors), 
who remain important ‘thinkers’ (although leadership must come from the 
Ministers of Health and/or Science). 
 
There are many barriers to bringing a product to market; in addition to 
scientific uncertainty, there are financial pressures, questions about how 
cellular products might be tested (deployed in clinical trials and under clinical 
trial regulation), and so on.  Policymakers must be aware of how different 
considerations and regimes affect basic science and its transition to applied 
science (eg: marketing or market access regulation and commercialisation 
"There is 
significant 
scientific and 
technical 
uncertainty in the 
cellular products 
setting, and so 
there will 
inevitably be 
regulatory 
uncertainty.  
This makes 
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between and 
amongst 
stakeholders 
essential." 
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regulation are all relevant).  Thus, it is useful for policymakers to consider how 
innovators are looking forward to markets, and to map routes into that market; 
again, this reflects the need to have open lines of communication between 
regulators and stakeholders (understood in the widest sense).  Open 
communication (including scientific exchange) needs to be encouraged around 
issues of quality, safety, and efficacy, as well as values and social objectives. 
 
Argentina might avoid the sense that the landscape is always shifting by 
encouraging communication and measuring stakeholder experiences, all of 
which will be helpful in terms of risk identification and management, including 
risks associated with investment.  Communication serves as a shaping tool; 
even if some instruments within the regulatory framework are sub-optimal 
(because they articulate expectations at a point in time), communication 
permits scientifically-grounded changes to be negotiated. 
 
Goal-Oriented Regulation 
Regulatory frameworks must be alive to new scientific innovations, but their 
responses to these innovations must be conservative, taking account of their 
primary duty to public health and the control of quality, safety, and efficacy of 
medicinal products.  Technocratic reactions to new scientific insights tend to 
be cumulative; they lead to new levels of oversight and therefore to increased 
regulatory load.  The Working Group was unable to identify an example where 
regulatory load was reduced as a result of technical developments or 
reflexively examining the field and saying ‘this isn’t working any more’.5  
Importantly, increased regulatory demands (including increased data submitted 
by industry and increased data demands to satisfy regulatory hurdles) have not, 
on the whole, resulted in better decisions or more innovation, when regulators 
made decisions on much smaller dossiers, medicines were approved and no 
great catastrophes were suffered.6 
 
While fragmentation of decision-making, accumulation of regulatory load, and 
inflexibility of frameworks hampered the EU in the early days (1975-1985), 
and to some extent remain ongoing challenges, the value of harmonisation 
amongst the member states is demonstrated by the development of common 
legislation and useful cross-jurisdictional debates which have lead to 
harmonised approaches.  This can only be achieved if there are clear 
social/regulatory objectives and a framework that transparently operates 
3
5  The idea behind GMO regulation in the EU was to start strict and at the lower level 
(ie: put regulatory criteria in annexes and through them require industry/scientific applicants 
to provide technical detail because regulators were unclear what they should be asking).  The 
idea was that the specifics could be changed easily and this stringency could be reduced, but 
the reality is that the guidelines have been strengthened/toughened rather than clarified and 
streamlined. 
6  Thus, it is difficult to see how an increased corpus of information has helped the 
regulatory processes (or helped science achieve its ends). 
"Technocratic 
reactions to new 
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toward those objectives.  One stated objective has been the EU’s emphasis on 
strengthening the single market, which has meant that the system shepherds 
innovations toward the market.  Here political leadership is important; 
‘checking in with the polity’ lends it greater legitimacy when setting up 
evaluation procedures and making decisions about the sharing of risk burdens 
(both of which are part of an integrated quality management system). 
 
Potential system designers like Argentina might take notice of the 
requirements of the International Conference on Harmonisation (ICH – started 
in 1990), which will be important with respect to getting into the international 
scene; Argentina will need the provinces to come on board and join a uniform 
system.  Additionally, Argentina may wish to acknowledge the importance and 
value of a uniform clinical trials framework.  However, it should also 
recognise that novel materials (like cellular products) might need a different 
and more streamlined approach to clinical trials; the EU has been hampered in 
its clinical trials of novel materials because of the complexity of the 
responsibility of such trials being left to each member state, which adds to the 
development costs of clinical trials. 
 
RECOMMENDATIONS 
 
Argentina is in a unique and enviable position in that it has the opportunity to 
design a rational and streamlined cellular products system from the bottom up.  
Based on the discussions, the authors would recommend the following policy 
actions for Argentina: 
 
• Recommendation 1: A Sui Generis Framework: Cellular products 
will begin as one thing (eg: something specialised for individual 
patients), and, as they are better understood, will become something 
else (eg: something mass produced for the public health setting), so 
regulation governing them might best be approached on a sui generis 
basis which does not mimic the terms and complexity of more ad hoc 
systems.  The Working Group does not endorse the unaltered adoption 
of the EU approach, but there is value in being aware of the EU system 
so that a fit-for-purpose and internationally reliable Argentine system 
can be designed.  A sui generis framework might adopt an holistic 
approach that provides guidance from basic research, through product 
development to product market and beyond, the broad view of which 
can allow Argentina to continue to improve the system and encourage 
innovation as science and understanding progress. 
 
• Recommendation 2: Regulatory Goals/Objectives: Argentina should 
dwell less on the definitional aspect of regulation and more on the 
objective of regulation broadly based so as not to inhibit progress (ie: 
"Political 
leadership will be 
important in 
designing a fit-for-
purpose 
regulatory regime, 
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core values and 
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quality, safety, and 
efficacy of 
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the regulatory goals).  The objective must be to generate new 
knowledge and to develop new responses to disease and illness within a 
value environment that suits the polity (ie: it must be to encourage the 
ethical development of products that can efficiently be distributed 
throughout Argentine and international markets).  In order to do so, key 
regulatory aims must be to: (1) articulate a broad value base (supported 
by the civil law); (2) explicitly promote innovation;7 (3) embed and 
specify quality standards for both research and products; (4) ensure 
safety of products for human application; (5) maximise (and test) the 
efficacy of products; and (6) identify and manage risk (which involves 
negotiated risk sharing). 
 
• Recommendation 3: Single Regulatory Entity: A single entity tasked 
with regulating all aspects of regenerative medicine (from research to 
marketing of cellular products) may be optimal,8 but that entity would 
have to have value guidance, clear authority, and, supremely important, 
open lines of communication with ‘stakeholders’9 so that the 
framework can be co-produced.  Open and ongoing communication 
between the stakeholders is vitally important so that parties can jointly 
work toward regulatory/social goals.   This single entity should have a 
clear mission statement, a good management structure, and an 
integrated quality management system. 
 
• Recommendation 4: Harmonising Clinical Trials Law: In addition 
to a regenerative medicine regime, Argentina needs a federal clinical 
trials law which is applicable to the provinces and serves to harmonise 
instruments and practices within the provinces, assuring protection of 
fundamental rights of the subjects of research. 
 
The Working Group concluded that the problem isn’t knowing what the 
problem is but marshalling the political will to move, and knowing in what 
direction to move – Argentina is well placed because of its current political 
actors and growing technical/regulatory understanding. 
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7  It was agreed that identifying innovation promotion, knowledge generation, 
innovation promotion, and treatment/therapy development as national goals in the preamble 
or recitals of a law is important because this signals core objectives, and creates expectations 
around the regulation.  The philosophy of the framework should also be apparent (eg: will it 
be a light-touch system that can be modified through experience).  This corresponds with our 
data from Argentina that stakeholders think the law should enumerate values and objectives. 
8  A single entity with multiple roles will often be more efficient and effective than 
multiple entities with narrower roles which then have to coordinate. 
9  Those who are being regulated, including industry, scientists/researchers, patient 
groups. 
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